Your browser is no longer supported. Please, upgrade your browser.
NRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own1.40% Shs Outstand47.46M Perf Week-38.72%
Market Cap483.03M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float7.68M Perf Month30.64%
Income-2.30M PEG- EPS next Q- Inst Own2.60% Short Float1.85% Perf Quarter-60.78%
Sales- P/S- EPS this Y-596.10% Inst Trans- Short Ratio0.04 Perf Half Y-74.16%
Book/sh0.45 P/B33.73 EPS next Y- ROA-37.00% Target Price- Perf Year42.54%
Cash/sh0.00 P/C- EPS next 5Y- ROE-88.80% 52W Range8.39 - 76.99 Perf YTD-37.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.28% Beta0.02
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low80.93% ATR3.16
Employees2 Current Ratio0.10 Sales Q/Q- Oper. Margin- RSI (14)50.69 Volatility26.38% 23.37%
OptionableNo Debt/Eq2.42 EPS Q/Q-446.10% Profit Margin- Rel Volume1.00 Prev Close15.15
ShortableNo LT Debt/Eq2.42 Earnings- Payout- Avg Volume3.88M Price15.18
Recom- SMA2018.03% SMA50-7.12% SMA200-38.09% Volume3,868,085 Change0.20%
Jul-27-21 11:34AM  
Jul-22-21 06:48AM  
Jul-19-21 06:48AM  
Jul-12-21 11:18AM  
Jul-06-21 09:20AM  
Jun-15-21 07:33AM  
Jun-09-21 02:50PM  
Jun-08-21 02:03PM  
Jun-07-21 01:45PM  
Jun-01-21 06:28AM  
May-27-21 06:48AM  
May-26-21 09:29AM  
NRx Pharmaceuticals, Inc. a clinical-stage, small molecule pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.